Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 901–1,000 of 1,044
Macchi, C., Ferri, N., Favero, C., Cantone, L., Vigna, L., Pesatori, A. C., Lupo, M. G., Sirtori, C. R., Corsini, A., Bollati, V., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318815320 · Cited by 42
Figarska, S. M., Rigdon, J., Ganna, A., Elmståhl, S., Lind, L., Gardner, C. D., & Ingelsson, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-64636-7 · Cited by 42
Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia
Karpale, M., Hukkanen, J., & Hakkola, J. (2022) · Cells · doi:10.3390/cells11030313 · Cited by 42
von Eckardstein, A., & Binder, C. J. (2022) · Handbook of experimental pharmacology · doi:10.1007/978-3-030-86076-9 · Cited by 42
Jia, Y., Liu, J., Guo, Y., Xu, R., Sun, J., & Li, J. (2013) · PubMed Central · doi:10.3969/j.issn.1671-5411.2013.04.007 · Cited by 42
Guardiola, M., Plana, N., Ibarretxe, D., Cabré, A., González, M., Ribalta, J., & Masana, L. (2015) · Clinical Science · doi:10.1042/cs20140832 · Cited by 42
Proprotein convertases as therapeutic targets
Chrétien, M., Seidah, N. G., Basak, A., & Mbikay, M. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.10.1289 · Cited by 42
Self-citationRecent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 42
Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia
Taylor, A., Tabrah, S., Wang, D., Sozen, M., Duxbury, N. J., Whittall, R., Humphries, S. E., & Norbury, G. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00807.x · Cited by 42
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Jänis, M. T., Tarasov, K., Ta, H. X., Suoniemi, M., Ekroos, K., Hurme, R., Lehtimäki, T., Päivä, H., Kleber, M. E., März, W., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.029 · Cited by 41
Self-citationBai, J., Na, H., Hua, X., Wei, Y., Ye, T., Zhang, Y., Jian, G., Zeng, W., Yan, L., & Tang, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.14322 · Cited by 41
Vuorio, A., & Kovanen, P. T. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13210 · Cited by 41
Cross-species data integration to prioritize causal genes in lipid metabolism
Votava, J. A., & Parks, B. W. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000742 · Cited by 41
Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome
Chen, Y., Wang, G., Chen, J., Wang, C., Dong, X., Chang, H., Yuan, S., Zhao, Y., & Mu, L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae002 · Cited by 41
PCSK9: A key factor modulating atherosclerosis
Li, S., & Li, J.-J. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.27615 · Cited by 41
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 35
PCSK9 and triglyceride-rich lipoprotein metabolism
Irena, D., Hussein, A., & Ooi, T. C. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150052 · Cited by 41
Familial Hypercholesterolemia in Asian Populations
Zhou, M., & Zhao, D. H. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34405 · Cited by 41
Poirier, S., Hamouda, H. A., Villeneuve, L., Demers, A., & Mayer, G. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157230 · Cited by 33
Girona, J., Ibarretxe, D., Plana, N., Guaita‐Esteruelas, S., Amigó, N., Heras, M., & Masana, L. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0428-z · Cited by 41
ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia
Paquette, M., Dufour, R., & Baass, A. W. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.001 · Cited by 41
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Zheng-Lin, B., & Ortíz, A. (2018) · Drugs · doi:10.1007/s40265-017-0858-2 · Cited by 41
Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
Gupta, K. K., Ali, S., & Sanghera, R. S. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0123-0 · Cited by 41
Cheng, F., Ma, Y., Uzzi, B., & Loscalzo, J. (2020) · BMC Biology · doi:10.1186/s12915-020-00868-3 · Cited by 41
The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis
Verberk, S. G. S., Kuiper, K. L., Lauterbach, M., Latz, E., & den Bossche, J. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.09.004 · Cited by 41
Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism
González-Lleó, A. M., Sánchez-Hernández, R. M., Boronat, M., & Wägner, A. M. (2022) · Nutrients · doi:10.3390/nu14071503 · Cited by 41
Ooi, T. C., Raymond, A., Cousins, M., Favreau, C., Taljaard, M., Gavin, C., JOLLY, E. E., Malone, S. C., Eapen, L. J., Chrétien, M., et al. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.03.036 · Cited by 41
Genetic Variation and Atherosclerosis
Biroš, E., Karan, M., & Golledge, J. (2008) · Current Genomics · doi:10.2174/138920208783884856 · Cited by 41
Talmud, P. J., Futema, M., & Humphries, S. E. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000090 · Cited by 41
Weider, E., Susan-Resiga, D., Essalmani, R., Hamelin, J., Asselin, M.-C., Nimesh, S., Ashraf, Y., Wycoff, K. L., Zhang, J., Prat, A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.717736 · Cited by 34
Self-citationElbitar, S., Susan‐Resiga, D., Ghaleb, Y., Khoury, P. E., Peloso, G. M., Stitziel, N. O., Rabès, J., Carreau, V., Hamelin, J., Ouadda, A. B. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20281-9 · Cited by 41
Self-citationPCSK9 inhibitors – past, present and future
Reiner, Ž. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1075506 · Cited by 41
Vogel, R. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.011 · Cited by 41
Human Genomics and Drug Development
Schmidt, A. F., Hingorani, A. D., & Finan, C. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039230 · Cited by 41
Katzmann, J. L., Cupido, A. J., & Laufs, U. (2022) · Metabolites · doi:10.3390/metabo12010070 · Cited by 40
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
Lepor, N. E., & Kereiakes, D. J. (2015) · PubMed · Cited by 40
Kosmas, C. E., DeJesus, E., Morcelo, R., Garcia, F., Montan, P. D., & Guzman, E. (2017) · Drugs in Context · doi:10.7573/dic.212511 · Cited by 40
Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
Khoshnejad, M., Patel, A., Wojtak, K., Kudchodkar, S. B., Humeau, L., Lyssenko, N. N., Rader, D. J., Muthumani, K., & Weiner, D. B. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.016 · Cited by 39
Vuorio, A. F., Watts, G. F., & Kovanen, P. T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.040 · Cited by 40
Identifying cross-disease components of genetic risk across hospital data in the UK Biobank
Cortés, A., Albers, P. K., Dendrou, C. A., Fugger, L. H., & McVean, G. (2019) · Nature Genetics · doi:10.1038/s41588-019-0550-4 · Cited by 40
Synthetic immunomodulation with a CRISPR super-repressor in vivo
Moghadam, F., LeGraw, R., Velazquez, J. J., Yeo, N. C., Xu, C., Park, J. H., Chavez, A., Ebrahimkhani, M. R., & Kiani, S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0563-3 · Cited by 40
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 40
Genetic backgrounds and diagnosis of familial hypercholesterolemia
Rogozik, J. K., Główczyńska, R., & Grabowski, M. (2023) · Clinical Genetics · doi:10.1111/cge.14435 · Cited by 40
Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion
Cameron, J., Holla, Ø. L., Berge, K. E., Kulseth, M. A., Ranheim, T., Leren, T. P., & Laerdahl, J. K. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06553.x · Cited by 33
Chorba, J. S., & Shokat, K. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594861 · Cited by 36
Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury
Le Bras, M., Roquilly, A., Deckert, V., Langhi, C., Feuillet, F., Sébille, V., Mahé, P.-J., Bach, K., Masson, D., Lagrost, L., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4236 · Cited by 38
Al‐Rasadi, K., Al-Waili, K., Awan, Z. A., Valenti, D. A., Couture, P., & Genest, J. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.08.021 · Cited by 40
Chan, D. C., Hamilton, S. J., Rye, K. A., Chew, G. T., Jenkins, A. J., Lambert, G., & Watts, G. F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01229.x · Cited by 36
Millar, J. S., & Lagor, W. R. (2009) · Journal of Receptor Ligand and Channel Research · doi:10.2147/jrlcr.s6033 · Cited by 40
Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells
Leblond, F., Seidah, N. G., Précourt, L.-P., Delvin, E., Dominguez, M., & Levy, E. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90424.2008 · Cited by 30
Self-citationSafety and tolerability of injectable lipid-lowering drugs: a review of available clinical data
Cicero, A. F., Tartagni, E., & Ertek, S. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.932348 · Cited by 39
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
Unexpected roles for PCSK9 in lipid metabolism
Soutar, A. K. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834622b5 · Cited by 39
PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer’s disease
Courtemanche, H., Bigot, E., Pichelin, M., Guyomarch, B., Boutoleau-Bretonnière, C., Le May, C., Derkinderen, P., & Cariou, B. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170993 · Cited by 39
Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
Yang, Q., Wang, S., Liu, Y., Song, A., Wu, Z., Wan, S., Li, H., & Sun, Z. (2023) · iScience · doi:10.1016/j.isci.2023.106916 · Cited by 39
Page, M. M., Bell, D. A., Hooper, A. J., Watts, G. F., & Burnett, J. R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.004 · Cited by 39
Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679340 · Cited by 39
Photocontrol of Biological Activities of Protein by Means of a Hydrogel
Murayama, S., & Kato, M. (2010) · Analytical Chemistry · doi:10.1021/ac1003757 · Cited by 39
Hu, D., Yang, Y., & Peng, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.064 · Cited by 39
Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation
Roden, D. M., Driest, S. L. V., Wells, Q. S., Mosley, J. D., Denny, J. C., & Peterson, J. F. (2018) · Circulation Research · doi:10.1161/circresaha.117.310965 · Cited by 39
Croyal, M., Blanchard, V., Ouguerram, K., Chétiveaux, M., Cabioch, L., Moyon, T., Billon-Crossouard, S., Aguesse, A., Bernardeau, K., Le May, C., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313877 · Cited by 36
Self-citationAutocrine effects of PCSK9 on cardiomyocytes
Wolf, A., Kutsche, H. S., Schreckenberg, R., Weber, M., Li, L., Rohrbach, S., Schulz, R., & Schlüter, K.-D. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-00824-w · Cited by 36
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 39
A nuclear receptor facilitates differentiation of human PSCs into more mature hepatocytes
Ma, H., de Zwaan, E., Guo, Y. E., Cejas, P., Thiru, P., van de Bunt, M., Jeppesen, J. F., Syamala, S., Dall’Agnese, A., Abraham, B. J., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.03.015 · Cited by 39
Base Editing and Prime Editing: Potential Therapeutic Options for Rare and Common Diseases
Testa, L. C., & Musunuru, K. (2023) · BioDrugs · doi:10.1007/s40259-023-00610-9 · Cited by 39
Wei, J., Fu, Z.-Y., Li, P.-S., Miao, H.-H., Li, B.-L., Ma, Y.-T., & Song, B.-L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593764 · Cited by 33
Yang, K., Su, Y., Shew, J., Yang, K., Tseng, W., Wu, C., & Lee, Y. (2007) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(08)60044-3 · Cited by 39
Kappelle, P. J. W. H., Lambert, G. C., & Dullaart, R. P. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.028 · Cited by 39
Zhang, Y., Zhou, L., Kong-Beltran, M., Li, W., Moran, P., Wang, J., Quan, C. L., Tom, J., Kolumam, G. A., Elliott, J. M., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.06.018 · Cited by 39
PCSK9 and lipid lowering drugs
Guo, Y., Zhang, W., & Li, J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.07.008 · Cited by 39
Epigenetic modulation in the treatment of atherosclerotic disease
Byrne, M. M., Murphy, R. T., & Ryan, A. W. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00364 · Cited by 39
Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: Versión resumida
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2008) · Revista Española de Cardiología · Cited by 39
Moving Targets: Recent Advances in Lipid-Lowering Therapies
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 39
A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1
The French Research Network on ADH, Marques-Pinheiro, A., Marduel, M., Rabès, J.-P., Devillers, M., Villéger, L., Allard, D., Weissenbach, J., Guerin, M., Zair, Y., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.94 · Cited by 38
Self-citationMK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Burnett, J. R., & Hooper, A. J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267972 · Cited by 38
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 38
JCS/JCC/JSPCCS 2024 Guideline on Genetic Testing and Counseling in Cardiovascular Disease
Imai, Y., Kusano, K., Aiba, T., Ako, J., Asano, Y., Harada‐Shiba, M., Kataoka, M., Kosho, T., Kubo, T., Matsumura, T., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0926 · Cited by 38
Emerging oral therapeutic strategies for inhibiting PCSK9
Ferri, N., & Marodin, G. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.11.003 · Cited by 38
Insights from exome sequencing for endocrine disorders
de Bruin, C., & Dauber, A. N. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.72 · Cited by 38
Navarese, E. P., Kołodziejczak, M. M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito, F., Sionís, A., & Ciccone, M. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv045 · Cited by 38
PCSK 9 in diabetic kidney disease
Elewa, U., Fernández‐Fernández, B., Mahíllo, I., Martín-Cleary, C., Sanz, A. B., Sánchez-Niño, M. D., & Ortíz, A. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12661 · Cited by 38
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Wang, Y., & Liu, Z. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180423111442 · Cited by 38
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 39
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
Oleaga, C., Shapiro, M. D., Hay, J., Mueller, P. A., Miles, J., Huang, C., Friz, E., Tavori, H., Toth, P. P., Wójcik, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.056 · Cited by 38
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
He, N.-Y., Li, Q., Wu, C., Ren, Z., Gao, Y., Pan, L.-H., Wang, M., Wen, H.-Y., Jiang, Z., Tang, Z., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.134 · Cited by 38
Alirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 38
Hyrina, A., Olmstead, A. D., Steven, P., Krajden, M., Tam, E., & Jean, F. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.08.020 · Cited by 36
Lowering Plasma Cholesterol by Raising LDL Receptors — Revisited
Young, S. G., & Fong, L. G. (2012) · New England Journal of Medicine · doi:10.1056/nejme1202168 · Cited by 36
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032031 · Cited by 37
Cho, L., Rocco, M. B., Colquhoun, D., SULLIVAN, D. R., Rosenson, R. S., Dent, R. E., Xue, A. X., Scott, R. C., Wasserman, S. M., & Stroes, E. S. G. (2014) · Clinical Cardiology · doi:10.1002/clc.22248 · Cited by 37
New Approaches in Detection and Treatment of Familial Hypercholesterolemia
Hartgers, M. L., Ray, K. K., & Hovingh, G. K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0665-x · Cited by 37
Investigating the Metabolic Syndrome: Contributions of Swine Models
Zhang, X., & Lerman, L. O. (2016) · Toxicologic Pathology · doi:10.1177/0192623316630835 · Cited by 37
Chae, H., You, B. H., Kim, D.-Y., Lee, H., Ko, H. W., Ko, H., Choi, Y. H., Choi, S. S., & Chin, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-24935-6 · Cited by 37
CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets
Rubbini, D., Cornet, C., Terriente, J., & Donato, V. D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220926920 · Cited by 37
Functional validation of new pathways in lipoprotein metabolism identified by human genetics
Bauer, R. C., Stylianou, I. M., & Rader, D. J. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834469b3 · Cited by 36
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Genetic Heterogeneity of Autosomal Dominant Hypercholesterolemia in Mexico
Robles-Osorio, L., Huerta-Zepeda, A., Ordóñez, M. L., Canizales-Quinteros, S., Díaz-Villaseñor, A., Gutiérrez-Aguilar, R., Riba, L., Huertas-Vázquez, A., Rodríguez-Torres, M., Gómez-Díaz, R. A., et al. (2006) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.04.018 · Cited by 35
Self-citationSusan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769430 · Cited by 35
Self-citationIdentification of Novel Genes and Pathways Regulating SREBP Transcriptional Activity
Chatterjee, S., Szustakowski, J. D., Nanguneri, N. R., Mickanin, C., Labow, M. A., Nohturfft, A., Dev, K. K., & Sivasankaran, R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005197 · Cited by 35
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.